Compare Amgen, Inc. (AMGN) vs Canadian National Railway Co. (CNI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Canadian National Railway Co. — how do they compare? Amgen, Inc. trades at $356.07 (market cap $196.12B), while Canadian National Railway Co. trades at $124.78 (market cap $75.28B). The key difference: Amgen, Inc. is far larger — about 2.6× Canadian National Railway Co.'s market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | CNI | |
|---|---|---|
Market Cap | $196.12B | $75.28B |
Sector | Health | Industrials |
52-Week High | $388.16 | $124.40 |
52-Week Low | $271.18 | $90.91 |
Enterprise Value | $241.41B | $90.74B |
Dividend Yield | 2.77% | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
CNI trades at $124.40, up 0.05% with a bullish technical outlook. The company reported Q1 2026 EPS of $1.31, meeting expectations, and maintains strong profitability with a 27.23% net margin. Recent news highlights record propane shipments and a new potash transport agreement with BHP, signaling operational strength. Analyst consensus is a Buy with a $143.71 price target, implying 15.5% upside from current levels.
The stock presents a solid long-term opportunity driven by operational efficiency and strategic growth initiatives, though elevated valuation multiples and rising debt levels warrant caution. Near-term performance hinges on Q2 2026 earnings due July 24, 2026, with market sentiment leaning positive amid sustainable dividend payments and institutional support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Canadian National Railway Co.
Canadian National's railway spans Canada from coast to coast and extends through Chicago to the Gulf of Mexico. In 2019, CN delivered almost 6 million carloads over its 19,600 miles of track. CN generated roughly CAD 14 billion in total revenue by hauling intermodal containers (25% of consolidated revenue), petroleum and chemicals (21%), grain and fertilizers (16%), forest products (12%), metals and mining (11%), automotive shipments (6%), and coal (4%). Other items constitute the remaining revenue.
Read more on CNI →
